CA-KALRAY
4.8.2022 08:32:04 CEST | Business Wire | Press release
Kalray (Euronext Growth Paris : ALKAL) (Paris:ALKAL) , a leading provider of the new generation of processors and acceleration cards specialized in Intelligent Data Processing from Cloud to Edge, is delighted to announce it has won the coveted Flash Memory Summit award for most innovative technology.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220803005573/en/
Flash Memory Summit (FMS) is the world's premier flash memory conference and exposition, held at the Santa Clara Convention Center, California, USA. The Flash Memory Summit Awards represent an industry recognition of innovation that Kalray’s Flashbox™ solution brings to the market.
“Designing an enterprise storage array today can benefit from a disaggregated architecture that can address performance at the highest levels and capacity expansion in a cost-effective manner.” said Jay Kramer, Chairman of the Awards Program and President of Network Storage Advisors Inc. “We are proud to recognize the collaboration between Viking and Kalray which provides an integrated storage solution delivering seral millions of IOPS using 12x 100 Gb/s network interface connections distributed across six DPUs-based acceleration cards.”
Flashbox™ is a new concept of All-Flash-Array, based on Kalray’s MPPA® DPU processor (“Data Processing Unit”) and co-designed with Viking Enterprise Solutions.
Whereas most advanced All-Flash Array solutions currently use multiple adapter cards with power-hungry and expensive CPUs (x86) that run storage services, the concept of Flashbox™ is to run all of the critical functions of a disaggregated storage appliance on a single chip: the Kalray MPPA® DPU. This solution delivers an unprecedent level of integration, speed, scalability and performance at an affordable cost. Thanks to Flashbox™ All-Flash-Array, data centers can reduce critical metrics such as $/IOP and IOPs/watt.
“It is a great honor to win a Flash Memory Summit award for our innovative concept of Flashbox™ All-Flash Array.” said Kalray CEO, Éric Baissus. “We strongly believe that wide adoption of NVMe requires adopting new innovative approaches. This is Flashbox™. Flashbox™ is a unique high-performance, low power, cost-effective, high-available new generation of storage appliances based on Kalray’s DPU technology. Powered by our Smart Storage Acceleration Card, Flashbox™ allows data center customers to disaggregate their Flash tier while maintaining the same performance of local NVMe, thereby optimizing both Flash performance and capacity across the compute tier of their data center.”
A unique concept on the market today, Flashbox™ benefits from ultra-fast interfaces and low power consumption. It can deliver unprecedent performance figures using 12x 100 Gb/s network interface connections distributed across six K200-LP cards and is based on market standards such as Storage Performance Development Kit (SPDK), NVMe/TCP or RDMA over Converged Ethernet (RoCEv1/v2).
Flashbox™ is a 2U array, with support for 24 U.2 NVMe SSDs. Flashbox™ JBOF (Just A Bunch of Flash) replaces x86 servers of traditional storage nodes with Kalray PCIe cards (K200-LP) which incorporate the Kalray DPU. The high-availability Flashbox™ has two Viking Enterprise Solutions fabric modules, each module has a PCIe switch network and supports three PCIe add-in card slots (half-height, half-length). Each Kalray DPU PCIe add-in card can run all the critical functions and data services required of a storage appliance. Flashbox™ can scale from two to six of the K200-LP PCIe add-in cards allowing the end customer to scale performance independently of capacity of the array. This unique solution is lower cost and significantly lower power from a traditional NVMe storage array.
Additionally, users will be able to take advantage of current and future data services integrated into the solution software stack such as data reduction (compression or deduplication), data availability (RAID or erasure encoding) or data security (encryption). This will further enhance critical business metrics by offloading these services from the data center compute tiers. Flashbox™ offers the ideal SDS (software defined storage) solution by abstracting and disaggregating the Flash tier from the compute tier.
About KALRAY
Kalray (Euronext Growth Paris - FR0010722819 - ALKAL) is a fabless semiconductor company, a leading provider of a new class of processors, specialized in Intelligent Data Processing from Cloud to Edge. Kalray’s team have created and developed its leading-edge technology and products to help its clients maximize the market possibilities presented by a world dominated by massive, disparate and pervasive data.
Thanks to Kalray’s patented manycore architecture, Kalray’s MPPA® Intelligent Data Processors are natively capable of managing multiple workloads with no bottlenecks to enable smarter, more efficient and energy-wise data-intensive applications. Kalray's offering includes processors, acceleration cards with associated software environment and appliances, allowing its customers to design the best solutions in fast growing sectors such as modern data centers, 5G, AI and Edge Computing, autonomous vehicles and others.
Founded in 2008 as a spin-off of CEA French lab, with investors such as Alliance Venture (Renault-Nissan-Mitsubishi), Safran, NXP Semiconductors, CEA and Bpifrance, Kalray is dedicated through technology, expertise and passion to offer more: More for a smart world, more for the planet, more for customers and developers. www.kalrayinc.com
About Viking Enterprise Solutions
Viking Enterprise Solutions, a product division of Sanmina Corporation, provides advanced data center products including solid-state memory and disk-based storage server appliances, JBOD storage systems and other products for a variety of data center and storage applications. Viking Enterprise Solutions award winning products are tailored for integration into OEM, system integrator and data center products, reducing development and operating costs while improving time-to-market. www.vikingenterprisesolutions.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220803005573/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom